[
    [
        {
            "time": "2018-03-15",
            "original_text": "Zacks.com featured highlights include: Genesco, Target, Eli Lilly, Pan American and ChannelAdvisor",
            "features": {
                "keywords": [
                    "Genesco",
                    "Target",
                    "Eli Lilly",
                    "Pan American",
                    "ChannelAdvisor"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "retail",
                    "pharmaceuticals",
                    "technology"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "News_content": "Zacks.com featured highlights include: Genesco, Target, Eli Lilly, Pan American and ChannelAdvisor",
                "Correlation": 6,
                "Sentiment": 5,
                "Importance": 5,
                "Impact": 4,
                "Duration": 3,
                "Entity_Density": 8,
                "Market_Scope": 4,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        },
        {
            "time": "2018-04-10",
            "original_text": "Moving Average Crossover Alert: Eli Lilly and Company",
            "features": {
                "keywords": [
                    "Moving Average",
                    "Crossover",
                    "Eli Lilly"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Moving Average Crossover Alert: Eli Lilly and Company",
                "Correlation": 9,
                "Sentiment": 5,
                "Importance": 7,
                "Impact": 7,
                "Duration": 5,
                "Entity_Density": 9,
                "Market_Scope": 3,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "2018-05-22",
            "original_text": "Incyte (INCY) Surges 44% YTD on Jakafi's Strong Performance",
            "features": {
                "keywords": [
                    "Incyte",
                    "Jakafi",
                    "Strong Performance"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Incyte (INCY) Surges 44% YTD on Jakafi's Strong Performance",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 9,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 5,
                "Time_Proximity": 9,
                "Headline_Structure": 9,
                "Source_Recency": 9
            }
        },
        {
            "time": "2018-06-18",
            "original_text": "Pharma Companies Are Rushing to Treat a Little-Known Liver Disease. Investors Should Be Skeptical.",
            "features": {
                "keywords": [
                    "Pharma Companies",
                    "Liver Disease",
                    "Skeptical"
                ],
                "sentiment_score": -0.5,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "News_content": "Pharma Companies Are Rushing to Treat a Little-Known Liver Disease. Investors Should Be Skeptical.",
                "Correlation": 5,
                "Sentiment": 4,
                "Importance": 6,
                "Impact": 5,
                "Duration": 6,
                "Entity_Density": 4,
                "Market_Scope": 8,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        }
    ]
]